18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
Preliminary Study on the Diagnostic Value of 18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
Hunan Cancer Hospital
500 participants
Jan 1, 2024
OBSERVATIONAL
Conditions
Summary
To evaluate the potential usefulness of 18F-FAPI-04 positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging （PET/MR）for the diagnosis of primary and metastatic lesions, detection of recurrence or assessment of pathologic response in various types of cancer.
Eligibility
Inclusion Criteria1
- patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria1
- patients with non-malignant lesions; patients with pregnancy; the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
18F-FAPI-04 was injected into the patients before the PET/CT or PET/MR scans
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06557590